Skip to main content
. 2022 Sep 6;33(1):102–108. doi: 10.1136/ijgc-2022-003658

Table 2.

Indications for further investigation of targeted agents based on the outcomes of this review

Indication for further investigation Targeted agent
Further investigation warranted Bevacizumab
Cediranib
Trastuzumab
AZD1775
Further investigation may be warranted Pazopanib
Sunitinib
No evidence to support further investigation Abagovomab
Nintedanib
Lonafarnib
Erlotinib
Dasatinib